Susceptibility of Hermansky-Pudlak Mice to Bleomycin-Induced Type II Cell Apoptosis and Fibrosis

University of Cincinnati, Pulmonary, Critical Care, and Sleep Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267, USA.
American Journal of Respiratory Cell and Molecular Biology (Impact Factor: 4.11). 08/2007; 37(1):67-74. DOI: 10.1165/rcmb.2006-0469OC
Source: PubMed

ABSTRACT Pulmonary inflammation, abnormalities in type II cell and macrophage morphology, and pulmonary fibrosis are features of Hermansky-Pudlak Syndrome (HPS), a recessive disorder associated with intracellular trafficking defects. We have previously reported that "Pearl" (HPS2) and "Pale Ear" (HPS1) mouse models have pulmonary inflammatory dysregulation and constitutive alveolar macrophage (AM) activation (Young LR et al., J Immunol 2006;176:4361-4368). In the current study, we used these HPS models to investigate mechanisms of lung fibrosis. Unchallenged HPS1 and HPS2 mice have subtle airspace enlargement and foamy AMs, but little or no histologic evidence of lung fibrosis. Seven days after intratracheal bleomycin (0.025 units), HPS1 and HPS2 mice exhibited increased mortality and diffuse pulmonary fibrosis compared to strain-matched C57BL/6J wild-type (WT) mice. HPS mice had significantly increased collagen deposition, and reduced quasi-static and static compliance consistent with a restrictive defect. The early airway and parenchymal cellular inflammatory responses to bleomycin were similar in HPS2 and WT mice. Greater elevations in levels of TGF-beta and IL-12p40 were produced in the lungs and AMs from bleomycin-challenged HPS mice than in WT mice. TUNEL staining revealed apoptosis of type II cells as early as 5 h after low-dose bleomycin challenge in HPS mice, suggesting that type II cell susceptibility to apoptosis may play a role in the fibrotic response. We conclude that the trafficking abnormalities in HPS promote alveolar apoptosis and pulmonary fibrosis in response to bleomycin challenge.


Available from: Francis X Mccormack, Jun 08, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Rationale: The etiology of Hermansky-Pudlak syndrome (HPS) pulmonary fibrosis, a progressive interstitial lung disease with high mortality, is unknown. Galectin-3 is a beta-galactoside-binding lectin with pro-fibrotic effects. Objectives: To investigate the involvement of Galectin-3 in HPS pulmonary fibrosis. Methods: Galectin-3 was measured by ELISA, immunohistochemistry, and immunoblotting in human specimens from subjects with HPS and controls. Mechanisms of galectin-3 accumulation were studied by qRT-PCR, Northern blot analysis, membrane biotinylation assays, and rescue of HPS-1 deficient cells by transfection. Measurements and Main Results: Bronchoalveolar lavage Galectin-3 concentrations were significantly higher in HPS pulmonary fibrosis compared to idiopathic pulmonary fibrosis or normal volunteers and correlated with disease severity. Galectin-3 immunostaining was increased in HPS pulmonary fibrosis compared to idiopathic pulmonary fibrosis or normal lung tissue. Fibroblasts from subjects with HPS subtypes associated with pulmonary fibrosis had increased Galectin-3 protein expression compared to cells from non-fibrotic HPS subtypes. Galectin-3 protein accumulation was associated with reduced Galectin-3 mRNA, normal MUC1 levels, and upregulated miR-322 in HPS pulmonary fibrosis cells. Membrane biotinylation assays showed reduced Galectin-3 and normal MUC1 expression at the plasma membrane in HPS pulmonary fibrosis cells compared to control, which suggests that Galectin-3 is mistrafficked in these cells. Reconstitution of HPS1 cDNA into HPS1-deficient cells normalized Galectin-3 protein and mRNA levels as well as corrected Galectin-3 trafficking to the membrane. Conclusions: Intracellular Galectin-3 levels are regulated by HPS1 protein. Abnormal accumulation of Galectin-3 may contribute to the pathogenesis of HPS pulmonary fibrosis.
    American Journal of Respiratory Cell and Molecular Biology 10/2013; DOI:10.1165/rcmb.2013-0025OC · 4.11 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Hermansky–Pudlak syndrome (HPS) is an autosomal recessive disorder characterized by oculocutaneous albinism, bleeding tendency, and lysosomal accumulation of ceroid-like material, with occasional development of interstitial pneumonia (IP). Nine genetically distinct subtypes of HPS are known in humans; IP develops primarily in types 1 and 4. Most reported cases of HPS with IP are type 1, and there are no published reports of type 4 in Japanese individuals. A 58-year-old man with congenital oculocutaneous albinism and progressive dyspnea for 1 month was admitted to our hospital. We administered high-dose corticosteroids on the basis of a diagnosis of acute exacerbation of interstitial pneumonia. Respiratory symptoms and the findings of high-resolution computed tomography (CT) showed improvement. He was diagnosed with HPS type 4 with interstitial pneumonia on the basis of gene analysis. He has been receiving pirfenidone for 1 year and his condition is stable. This is the first report on the use of pirfenidone for HPS with IP caused by a novel mutation in the HPS4 gene. We conclude that HPS should be suspected in patients with albinism and interstitial pneumonia. High-dose corticosteroid treatment may be useful in cases of acute exacerbation of interstitial pneumonia due to HPS-4, and pirfenidone may be useful and well tolerated in patients with HPS-4.
    06/2013; 9:38–41. DOI:10.1016/j.rmcr.2013.04.002
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Interstitial lung fibrosis can develop as a consequence of occupational or medical exposures, as a result of genetic defects, following trauma or acute lung injury leading to fibroproliferative acute respiratory distress syndrome (ARDS) or can develop in an idiopathic manner. The pathogenesis of each of these forms of lung fibrosis is poorly understood. They each result in progressive loss of lung function with increasing dyspnea and ultimately, most forms result in mortality. To better understand the pathogenesis of lung fibrotic disorders, multiple animal models have been developed. This review summarizes common and emerging models of lung fibrosis to highlight their usefulness for understanding cell-cell and soluble mediator interactions which drive fibrotic responses. Recent advances have allowed for development of models to study targeted injury of type II alveolar epithelial cells, fibroblast autonomous effects and targeted genetic defects. Repetitive dosing in some models has more closely mimicked the pathology of human fibrotic lung disease. We also have a much better understanding of the fact that the aged lung increases susceptibility to fibrosis. Each of these models reviewed in this report offer a powerful tool to study some aspect of fibrotic lung disease.
    American Journal of Respiratory Cell and Molecular Biology 03/2013; DOI:10.1165/rcmb.2013-0094TR · 4.11 Impact Factor